An obesity drug from Hengrui Pharma and Kailera Therapeutics succeeded in a late-stage trial in China, while Anne Wojcicki’s ...

A promising experimental drug is one more sign of the impending disruption the booming Chinese biotech industry could bring ...

* Researchers at the Danish Headache Center are testing semaglutide along with a very low calorie diet as a treatment for new ...

Novo Nordisk named Maziar Mike Doustdar as its new chief executive on Tuesday, relying on an experienced company insider to ...

Novo Nordisk named Maziar Mike Doustdar as its new chief executive on Tuesday, relying on an experienced company insider to ...

In a surprise double announcement Tuesday, Novo reduced sales guidance by 5%—attributing the change to slowed growth of its ...

Novo Nordisk named Maziar Mike Doustdar as its new chief executive today, relying on an experienced company insider to revive sales and a share price hit by worries the maker of weight-loss drug ...

Business Insider spoke to Eli Lilly's new president of cardiometabolic health, who shared the company's aggressive incretin drug strategy.

Knockoff copies of Novo’s weight loss medicine Wegovy have held back sales and put the drugmaker on the back foot in its ...

COPENHAGEN (Reuters) -Investors knocked $70 billion off Novo Nordisk's market value on Tuesday after the maker of weight-loss ...

Since the US Food and Drug Administration (FDA) implemented a ban on ‘compounded’ versions of Wegovy on 22 May, new ...

The announcement came amid a slump in the company's share price and investor concerns about its experimental drug pipeline ...